PL3260865T3 - Method for the treatment of blood, blood products and organs - Google Patents

Method for the treatment of blood, blood products and organs

Info

Publication number
PL3260865T3
PL3260865T3 PL17172222.6T PL17172222T PL3260865T3 PL 3260865 T3 PL3260865 T3 PL 3260865T3 PL 17172222 T PL17172222 T PL 17172222T PL 3260865 T3 PL3260865 T3 PL 3260865T3
Authority
PL
Poland
Prior art keywords
blood
organs
treatment
products
blood products
Prior art date
Application number
PL17172222.6T
Other languages
Polish (pl)
Inventor
Dieter Willbold
Original Assignee
Priavoid Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210102999 external-priority patent/DE102012102999A1/en
Priority claimed from DE102012108599.4A external-priority patent/DE102012108599B4/en
Priority claimed from DE102012108598.6A external-priority patent/DE102012108598A1/en
Application filed by Priavoid Gmbh filed Critical Priavoid Gmbh
Publication of PL3260865T3 publication Critical patent/PL3260865T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/16Physical preservation processes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
PL17172222.6T 2012-04-05 2013-04-05 Method for the treatment of blood, blood products and organs PL3260865T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE201210102999 DE102012102999A1 (en) 2012-04-05 2012-04-05 Treating blood, blood products and/or organs under in vitro, and ex vivo condition, involves obtaining blood, blood products and/or organs from human or animal body and removing amyloid beta oligomers from products
DE102012108599.4A DE102012108599B4 (en) 2012-09-14 2012-09-14 A-beta oligomer-binding peptides and their use
DE102012108598.6A DE102012108598A1 (en) 2012-09-14 2012-09-14 New D3-D enantiomeric peptides derived from D3 and their use

Publications (1)

Publication Number Publication Date
PL3260865T3 true PL3260865T3 (en) 2023-04-11

Family

ID=48184148

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17172222.6T PL3260865T3 (en) 2012-04-05 2013-04-05 Method for the treatment of blood, blood products and organs

Country Status (8)

Country Link
US (3) US9591845B2 (en)
EP (2) EP2834643B1 (en)
JP (3) JP2015518474A (en)
CN (2) CN108926749A (en)
DK (2) DK3260865T5 (en)
ES (2) ES2938886T3 (en)
PL (1) PL3260865T3 (en)
WO (1) WO2013150126A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (en) 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH New D3-D enantiomeric peptides derived from D3 and their use
CN108926749A (en) 2012-04-05 2018-12-04 于利希研究中心有限公司 The method for handling blood, blood products and organ
JP6434903B2 (en) 2012-04-05 2018-12-05 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングForschungszentrum Juelich GmbH D-peptide-containing polymer that binds to multivalent amyloid β and use thereof
DE102013016002A1 (en) * 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Cyclic amyloid beta-binding peptides and their use
US10995118B2 (en) 2013-09-26 2021-05-04 Forschungszentrum Juelich Gmbh Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease
DE102015003676A1 (en) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Specifically A-beta species-binding peptides for the therapy and / or diagnosis of Alzheimer's dementia
US10836979B2 (en) * 2016-07-06 2020-11-17 George Stantchev Apparatus and method for plant extraction
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
JP7774972B2 (en) * 2021-04-01 2025-11-25 禎弘 飯田 Artificial peptides with peptide bond cleavage activity and their use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5968820A (en) 1997-02-26 1999-10-19 The Cleveland Clinic Foundation Method for magnetically separating cells into fractionated flow streams
JP2002542349A (en) 1999-04-16 2002-12-10 ダブリューエム・マーシュ・ライス・ユニバーシティー Biodegradable poly (propylene fumarate) network cross-linked with poly (propylene fumarate) -diacrylate macromer
DE60126980T2 (en) * 2000-11-27 2007-11-08 Praecis Pharmaceuticals Inc., Waltham THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES
DE10117281A1 (en) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptide for the diagnosis and therapy of Alzheimer's dementia
US20040143093A1 (en) 2002-07-11 2004-07-22 Ralph Zahn Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (en) 2004-07-13 2006-01-15 Mattner Frank Dr Kit for prevention or treatment of Alzheimer's disease comprises means for inducing sequestration of amyloid beta in plasma and apheresis apparatus which exhibits an amyloid beta precursor protein receptor
DE102005009909A1 (en) 2005-03-01 2006-09-07 Heinrich-Heine-Universität Düsseldorf Compounds suitable for eliminating misfolded proteins
DE102005031429A1 (en) 2005-07-04 2007-01-11 Heinrich-Heine-Universität Düsseldorf Method for the selective determination of pathological protein deposits
DE102005063175A1 (en) 2005-07-29 2007-02-01 Hans-Werner Prof. Dr. Heinrich Separation of cells and bio-particles and/or molecules, for animals and biotechnology and medical diagnosis, adds functionalized micro-particles for recognition and bonding to be separated by membranes
US20070092508A1 (en) 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
DE102006015140A1 (en) 2006-03-31 2007-10-11 Philipps-Universität Marburg Heterocyclic compounds with activity against neurodegenerative diseases
WO2008116293A1 (en) 2007-03-23 2008-10-02 The Governors Of The University Of Alberta Multivalent heterobifunctional polymers and methods of their use
CN101538329B (en) 2008-03-20 2013-01-30 中国医学科学院基础医学研究所 Variable region sequence for novel anti-beta amyloid polypeptide antibody and coding sequence thereof
WO2010062570A2 (en) 2008-10-27 2010-06-03 Recombinant Technologies Llc COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
DE102008037564A1 (en) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Composition for the production of anti-amyloid beta-peptide antibodies with D-peptides
DE102009037015A1 (en) 2009-08-07 2011-02-17 Michael Hajek Apparatus and method for eliminating biologically harmful substances from body fluids
DE102010019336A1 (en) 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Agent for the treatment of Alzheimer's dementia
DE102010017130B4 (en) * 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid compound, its use and process for its preparation
CN102233128B (en) 2010-11-26 2013-04-17 王延江 Use of p75neurotrophin receptor-extracellular domain (p75NTR-ECD) in medicine for preventing and treating Alzheimer disease
JP6434903B2 (en) 2012-04-05 2018-12-05 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングForschungszentrum Juelich GmbH D-peptide-containing polymer that binds to multivalent amyloid β and use thereof
CN108926749A (en) * 2012-04-05 2018-12-04 于利希研究中心有限公司 The method for handling blood, blood products and organ

Also Published As

Publication number Publication date
ES2938886T3 (en) 2023-04-17
EP3260865A3 (en) 2018-05-09
EP2834643A2 (en) 2015-02-11
CN108926749A (en) 2018-12-04
US20170172139A1 (en) 2017-06-22
JP2015518474A (en) 2015-07-02
WO2013150126A3 (en) 2014-01-03
EP2834643B1 (en) 2019-10-23
US20190037835A1 (en) 2019-02-07
EP3260865B1 (en) 2022-12-28
DK3260865T5 (en) 2024-10-14
DK3260865T3 (en) 2023-02-27
US10772321B2 (en) 2020-09-15
JP2017222682A (en) 2017-12-21
US20150282477A1 (en) 2015-10-08
DK2834643T3 (en) 2020-02-03
EP3260865A2 (en) 2017-12-27
WO2013150126A2 (en) 2013-10-10
ES2773125T3 (en) 2020-07-09
CN104380110A (en) 2015-02-25
US10123530B2 (en) 2018-11-13
JP2020037582A (en) 2020-03-12
JP6997160B2 (en) 2022-02-03
JP6619394B2 (en) 2019-12-11
US9591845B2 (en) 2017-03-14

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for the treatment of tissue
IL265774B (en) Diagnosis, prevention and treatment of diseases of the joint
EP2890440A4 (en) Devices and methods for the treatment of vascular disease
SG10201800720YA (en) Blood treatment systems and methods
PL3260865T3 (en) Method for the treatment of blood, blood products and organs
IL236411B (en) Method and apparatus for dermatological treatment
EP2858719A4 (en) Systems and methods for tissue treatment
EP2916725A4 (en) Improved blood pressure monitor and method
GB201203005D0 (en) Medical apparatus and method
EP2879617A4 (en) Devices and methods for treating occlusion of the ophthalmic artery
EP2825242A4 (en) Devices and methods for the treatment of vascular defects
IL236021A0 (en) Method and system for treatment of biological tissue
IL238066A0 (en) Method and system for treating biological tissue
EP3084000A4 (en) Method of diagnosis and treatment
EP2891465A4 (en) Medical system and operation method
EP2867239A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
GB201001412D0 (en) Propolis and process for the treatment thereof
GB201415841D0 (en) Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue
IL243674A0 (en) Method for enzymatic treatment of tissue products
GB201121940D0 (en) Drug treating high blood pressure
GB201414506D0 (en) Process and method for the treatment of materials, materials thus obtained and uses of these materials
EP2997969A4 (en) Treatment agent and treatment method for intestinal examination or surgery
GB201309645D0 (en) Treatment of peripheral arterial disease and other conditions, and apparatus therefor
EP2913067A4 (en) Artificial blood vessel, and method for producing artificial blood vessel